Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 521 to 530 of 1106 total matches.

GlucoWatch Biographer: A Noninvasive Glucose Monitoring Device

   
The Medical Letter on Drugs and Therapeutics • May 14, 2001  (Issue 1104)
safety data are available. EDITOR: Mark Abramowicz, M.D. DEPUTY EDITOR: Gianna Zuccotti, M.D., M.P.H ...
An automatic, noninvasive, glucose-monitoring device (GlucoWatch Biographer) has been approved for marketing by the FDA. The manufacturer states that it is not meant to replace a regular blood glucose meter.
Med Lett Drugs Ther. 2001 May 14;43(1104):42 |  Show IntroductionHide Introduction

Initial Treatment of Parkinson's Disease:Wait Just a Minute

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 2001  (Issue 1108)
or 3 tablets daily of a levodopa formulation, based on data from retail pharmacies nationwide provided ...
Recent articles in the press have trumpeted a new era in the management of Parkinson's disease: dopamine agonists have now replaced levodopa for initial treatment.
Med Lett Drugs Ther. 2001 Jul 9;43(1108):59-60 |  Show IntroductionHide Introduction

Ophthalmic Cyclosporine (Restasis) for Dry Eyes

   
The Medical Letter on Drugs and Therapeutics • May 26, 2003  (Issue 1157)
and increase tear production in some patients with dry eye disease, but more convincing data are needed. Since ...
A cyclosporine 0.05% ophthalmic emulsion (Restasis - Allergan) has been approved by the FDA for use in patients with dry eye disease (keratoconjunctivitis sicca). This review begins with a discussion of the causes of dry eye disease and includes sections on the pharmacology, adverse effects and clinical trial results for ophthalmic cyclosporine. Cost information and recommendations for administering the drug are also presented. The review concludes with an overall assessment of the drug's efficacy, safety and cost.
Med Lett Drugs Ther. 2003 May 26;45(1157):42-3 |  Show IntroductionHide Introduction

Azelaic Acid (Finacea) for Rosacea

   
The Medical Letter on Drugs and Therapeutics • Sep 15, 2003  (Issue 1165)
% metronidazole cream (Noritate), according to data from retail pharmacies nationwide provided by NDCHealth, July ...
Azelaic acid 15% gel (Finacea Berlex) is now available in the US for treatment of mild to moderate rosacea. A 20% cream formulation of the drug (Azelex Allergan; Medical Letter 1996; 38:52) has been marketed here since 1996 for treatment of acne. The effectiveness of Finacea compared to its own vehicle and to metronidazole gel is discussed. Information on the drug's mechanism of action, adverse effects, dosage and cost are also included.
Med Lett Drugs Ther. 2003 Sep 15;45(1165):76 |  Show IntroductionHide Introduction

Amlodipine/Atorvastatin (Caduet)

   
The Medical Letter on Drugs and Therapeutics • Jul 05, 2004  (Issue 1186)
tablet/day, according to the most recent data (May 31, 2004) from retail pharmacies nationwide available ...
Caduet (Pfizer), a combination of the calcium-channel blocker amlodipine (Norvasc - Pfizer) and the HMG-CoA reductase inhibitor (statin) atorvastatin (Lipitor - Pfizer), is now available in the US. It was approved by the FDA for use in patients with indications for treatment with both amlodipine, which is used to treat hypertension and/or angina pectoris, and atorvastatin, which is used to treat dyslipidemia. The combination is bioequivalent to the 2 components taken separately.
Med Lett Drugs Ther. 2004 Jul 5;46(1186):56 |  Show IntroductionHide Introduction

Atomoxetine (Strattera) Revisited

   
The Medical Letter on Drugs and Therapeutics • Aug 16, 2004  (Issue 1189)
was first marketed, until more data become available, atomoxetine is best reserved for patients who ...
Atomoxetine (Strattera - Lilly), a nonstimulant drug that is not a controlled substance, was approved by the FDA in early 2003 for the treatment of attention deficit hyperactivity disorder (ADHD). At that time, The Medical Letter concluded that it was unclear whether atomoxetine was as effective as stimulants such as methylphenidate (Concerta, and others) (Medical Letter 2003; 45:11). Since then, the drug has been heavily advertised directly to the public for use in both children and...
Med Lett Drugs Ther. 2004 Aug 16;46(1189):65 |  Show IntroductionHide Introduction

Drugs for Kidney Stones

   
The Medical Letter on Drugs and Therapeutics • Nov 29, 2010  (Issue 1352)
) from the distal ureter. More data from larger randomized trials would be welcome. o 1. EM Worcester and FL Coe ...
Renal colic is a common problem in emergency departments. Stones <5 mm in diameter often pass spontaneously; stones >10 mm in diameter generally do not. The usual treatment for stones that do not pass is ureteroscopy with laser lithotripsy or shockwave lithotripsy. Some clinicians have suggested that off-label use of an oral alpha-adrenergic blocker such as tamsulosin (Flomax, and others) or calcium channel blocker such as nifedipine (Procardia XL, and others) could be tried first, with or without a corticosteroid. Both adrenoreceptors and calcium channels may have a role in the...
Med Lett Drugs Ther. 2010 Nov 29;52(1352):93-4 |  Show IntroductionHide Introduction

Lurasidone (Latuda) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Feb 21, 2011  (Issue 1358)
to be effective in treating schizophrenia, but published data are sparse and comparative trials are lacking ...
The FDA has approved lurasidone (Latuda - Sunovion), a new second-generation antipsychotic, for oral treatment of schizophrenia in adults.
Med Lett Drugs Ther. 2011 Feb 21;53(1358):13-4 |  Show IntroductionHide Introduction

Spinosad (Natroba) Topical Suspension for Head Lice

   
The Medical Letter on Drugs and Therapeutics • Jun 27, 2011  (Issue 1367)
(June 15, 2011) or based on the most recent data (May 31, 2011) from retail pharmacies nationwide ...
The FDA has approved spinosad 0.9% suspension (Natroba – ParaPro) for topical treatment of head lice infestation in patients ≥4 years old. It is available only by prescription.
Med Lett Drugs Ther. 2011 Jun 27;53(1367):50-1 |  Show IntroductionHide Introduction

Fentanyl Nasal Spray (Lazanda) for Pain

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011  (Issue 1379)
data (October 2011) from retail pharmacies nationwide available from Wolters Kluwer Health. 100 ...
The FDA has approved a nasal spray formulation of fentanyl (Lazanda – Archimedes) for management of breakthrough pain in adult cancer patients who are already receiving and are tolerant to opioid therapy. Fentanyl is already available in the US for intravenous, intrathecal, epidural, transdermal and oral transmucosal use.
Med Lett Drugs Ther. 2011 Dec 12;53(1379):99-100 |  Show IntroductionHide Introduction